Regenxbio prices expected $100M public offering

US biotech Regenxbio (Nasdaq: RGNX) on Friday announced the pricing of an underwritten public offering of 10,003,889 shares of its common stock at the price of $9.00 per share and 1,111,111 pre-funded warrants at a price of $8.9999 per warrant, in each case before underwriting discounts and commissions.

The gross proceeds to Regenxbio from the offering, before deducting the underwriting discounts and commissions and other offering expenses payable by Regenxbio, are expected to be around $100.0 million. The firm’s shares closed down 11.7% at $9.89 following the announcement.